Article | August 10, 2022

Pursuing Venture Philanthropy With Opus Genetics: The Business Of Biotech

Source: Cytiva
GettyImages-1307980860-dna-rna-vial-gene

While the advanced therapy space continues to grow by leaps and bounds, many of the drugs currently in the development pipeline are in danger of never reaching commercialization, owing to the relatively small patient populations they target. Overcoming the obstacles inherent to bringing rare disease treatments to market will require new, more agile approaches from players across the space.

Dr. Ben Yerxa, who recently joined The Business of Biotech podcast to explore the importance of pursuing patient-centered therapies that may lack broad commercial appeal, currently serves as CEO of three separate organizations: the Foundation Fighting Blindness; its venture arm, the Retinal Degeneration Fund; and a newly formed biotech, Opus Genetics. In this episode, Yerxa explores the strategies that will enable the scale-up of niche therapeutics that represent life-changing interventions for patients.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma